| Literature DB >> 33066795 |
Xiaoli Feng1, Yaqing Zhang2, Chao Zhang3, Xuan Lai2, Yanli Zhang1, Junrong Wu2, Chen Hu2, Longquan Shao4.
Abstract
BACKGROUND: Widespread biomedical applications of nanomaterials (NMs) bring about increased human exposure risk due to their unique physicochemical properties. Autophagy, which is of great importance for regulating the physiological or pathological activities of the body, has been reported to play a key role in NM-driven biological effects both in vivo and in vitro. The coexisting hazard and health benefits of NM-mediated autophagy in biomedicine are nonnegligible and require our particular concerns. MAIN BODY: We collected research on the toxic effects related to NM-mediated autophagy both in vivo and in vitro. Generally, NMs can be delivered into animal models through different administration routes, or internalized by cells through different uptake pathways, exerting varying degrees of damage in tissues, organs, cells, and organelles, eventually being deposited in or excreted from the body. In addition, other biological effects of NMs, such as oxidative stress, inflammation, necroptosis, pyroptosis, and ferroptosis, have been associated with autophagy and cooperate to regulate body activities. We therefore highlight that NM-mediated autophagy serves as a double-edged sword, which could be utilized in the treatment of certain diseases related to autophagy dysfunction, such as cancer, neurodegenerative disease, and cardiovascular disease. Challenges and suggestions for further investigations of NM-mediated autophagy are proposed with the purpose to improve their biosafety evaluation and facilitate their wide application. Databases such as PubMed and Web of Science were utilized to search for relevant literature, which included all published, Epub ahead of print, in-process, and non-indexed citations.Entities:
Keywords: Anticancer; Autophagy; Hazard; Medical benefit; Nanomaterials; Neurodegenerative disease; Non-coding RNAs; Physicochemical property; Pyroptosis
Mesh:
Year: 2020 PMID: 33066795 PMCID: PMC7565835 DOI: 10.1186/s12989-020-00372-0
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Fig. 1Literature search strategy. By searching the contents of four search boxes in two databases, 379 literatures were initially obtained. After refinement and exclusion, only the content directly related to this review was finally included (125 articles were obtained), which constituted the core literature of this paper. Moreover, other relevant literature is cited in appropriate places as a supplement
Fig. 2An overview of phagocytic and non-phagocytic pathways. a Phagocytosis occurs in macrophages through an actin-based mechanism involving interaction with various specialized cell surface receptors (such as mannose, IgG and complement receptors). The foreign particles recognized by specific receptors are internalized to form endocytic vesicles called phagosomes. The fusion of phagosomes with the lysosomal compartment leads to the formation of phagolysosomes, where the foreign particles are enzymatically degraded. b Clathrin-mediated endocytosis involves the formation of vesicles from triskelion clathrin-coated regions of the plasma membrane. After internalization, the clathrin are recycled back to the plasma membrane followed by movement of ingested materials from early endosome to late endosome, which finally fuse with lysosome to form the lysosome-endosome hybrid. The materials are then degraded by the low pH and enzyme-rich environment of the endo-lysosomal vesicle. C) Caveolin-mediated endocytosis involves internalization through caveolin (a dimeric protein) enriched invaginations. The cytosolic caveolin vesicle delivers its contents to endosomes to form caveosomes, which can transported along the cytoskeleton to the endoplasmic reticulum/golgi complex. D) Macropinocytosis involves the formation of large vesicles called macropinosomes, which occurs through actin filament driven plasma membrane protrusions. Through this pathway, the contents are degraded following fusion with the lysosomal compartment [28]. Reproduced with permission from Stern et al. (2012, BioMed Central) and had been partially adapted from Hillaireau and Couvreur (Cell. Mol. Life Sci. 2009, 66, 2873–2896)
In vitro toxicological studies of NPs mediated autophagy
| NPs | Size (nm) | Coating | Cell line | Dose(ug/mL) | Uptake | Autophagy alteration | Biological effects | References |
|---|---|---|---|---|---|---|---|---|
| Fullerenol | 2 | bare | porcine renal proximal cells | 0.1, 1, 10 nM | – | induction of autophagy autolysosome accumulation, LC3 ↑ | mitochondrial membrane potential and ATP depletion, oxidative stress, cytoskeleton disruption, cell death | [ |
| SiNPs | ∼58.4 ± 7.4 | bare | HepG2 cells | 6.25, 12.5, 25, 50, 100 | endocytose | induction of autophagy and blockade of autophagic flux autophagosome accumulation, LC3 ↑, P62 ↑ | impaired the lysosomal function | [ |
| GO | 500–800 | bare | PC12 cells | 40,50,60 | internalization | blockage of the autophagic flux, p62 ↑ | Impairment of lysosomal degradation Apoptosis | [ |
| CdTe-QDs | 15 | bare | HEK cells | 15, 30, 60 nM | endocytosis | induction of autophagy, LC3 ↑ | ER autophagy, unfolded protein response | [ |
| Fe3O4 NPs | 15 ~ 20 | bare | MCF-7 cells | 100 | endocytosis | induction of autophagy autophagosome accumulation | impair the function of the lysosome, mitochondrial damage, ER and Golgi stress | [ |
| GO-Ag NPs | 15 | bare | SH-SY5Y cells | 5 | – | induction of autophagy autophagosomes accumulation | mitichondrial dysfunction, ROS, DNA fragmentation, apoptosis | [ |
| TiO2 NPs | 15,50,100 | bare | HeLa cells | 10,50,100,500 | internalization | blockage of the autophagic flux, LC3 ↑ | lysosomal membrane permeabilization, α-synuclein accumulation | [ |
| GQDs | 3.28 ± 1.16 | barre | GC-2 cells TM-4 cells | 100 | – | blockade of autophagic flux autophagosome accumulation p62 ↑ | decreased the amount and enzymatic activity of cathepsin B, and inhibited lysosome proteolytic capacity | [ |
| AuNPs | 10, 25, 50 | bare | NRK cells | 1 nM | endocytosis | blockade of autophagic flux autophagosome accumulation, LC3 ↑, p62 ↑ | Impairment of lysosome degradation capacity, Lysosome alkalinization | [ |
| HA/β-Ga2O3:Cr3+ NPs | – | bare | SH-SY5Y cells | 1,5, 25, 50 | – | induction of autophagy, LC3 ↑, SQSTM/p62 ↑ | ROS, calpain activation and neuronal damage | [ |
| GCNs | outer diameter of 79 ± 6.6, inner diameter of 7 ± 0.8 | bare | A549 cells | 1, 10, 25, 50, 100 | endocytosis | blockage of autophagic flux autolysosome accumulation | ROS, cytoskeleton disruption, apoptosis | [ |
| SeNPs | 80.0 ± 12.3 nm | bare | HCT 116 cells | 2,5,10 μM | endocytosis | induction of autophagy, Beclin 1 ↑ | cell cycle arrest, apoptosis | [ |
| TiO2 NPs | 22.07 ± 8.93 | bare | BEAS-2B cells | 6.25, 12.5, 25 | internalization | induction of autophagy accumulation of autophagic vacuoles, LC3 ↑ | overexpressed miR34a, mitochondrial dysfunction, cell death | [ |
| PU NPs | 64.3 ± 0.8 | Carboxyl | macrophage cells | 10,50 | internalization | Induction of autophagy | Inhibition of inflammation and immune supression | [ |
| SPIONs | 60–80 | bare | Raw264.7 cells BMDMs | 10,20,50,100 | endocytosis | Induction of autophagy autophagosomes accumulation, LC3 ↑, ATG5 ↑ | Inflammatory responses | [ |
| GO | MGO:1089.9 ± 135.3 SGO: 390.2 ± 51.4 NGO:65.5 ± 16.3 GQDs:5 | bare | HUVECs | 1,5,10,25 | internalization | induction of autophagy, LC3 ↑ p62 ↓ | Apoptosis, Apoptotic cell death, ER stress | [ |
| 127 ± 4.7 | PEG. | MCF7 cells MDA-MB-231 cells | 4 | – | inhibition of autophagy, LC3 ↓ | apoptosis, suppressed Stathmin1 protein, decreases the microtubule instability, cancer cell death | [ |
Fig. 3The interactions between NM-mediated autophagy and other biological effects. NMs endocytosed into cells can impaire various organelles including golgi apparatus, endoplasmic reticulum, mitochondria and lysosomes. The damaged organelles are sequestered by primary autophagosomes, which are fused with lysosomes to form autolysosomes, leading to degradation or autophagic flux blockade occur. Autophagy dysfunction will further cause cell inflammation, oxidative stress, apoptosis and pyroptosis. NMs induced LMP can result in cytoplasmic acidification and release of Fe2+, which directly relate to autophagic flux blockage and further cell necrosis. The mitophagy dysfunction can lead to caspase 8 activation, which can inhibit the expression of RIPK3, thereby inhibiting necroptosis. NMs cause RNA damage through the deacetylation of autophagy-related proteins and DNA damage through accumulation of chromosome fragments, both activating the autophagy pathway. Impairment of cytoskeleton is mainly manifested by the damage of actin and the decreased expression of histone deacetylase-6, which eventually leads to the disorder of autophagic flux
Possible therapies of NM-mediated autophagy
| NPs | Size (nm) | Combined agent | Disease type | Target cells | Dose (ug/mL) | Animal models | Exposure method and time | Administration dose(mg/kg) | Autophagy alteration | Treatment effect | References |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UCNPs | – | bare | Atherosclerosis | foam cells | 8 | – | – | – | induction of autophagy LC3 ↑, beclin 1 ↑, P62 ↓ | ROS, enhanced the cholesterol efflux | [ |
| SPIO NPs | 207 ± 3 | bare | Lung cancer | A549 cells | 1.75 mg/ml | Female Balb/c mice (4–6 weeks old) | intraperitoneal injection for 30 days | 225 μg magnetite equivalent | induction of autophagy | in vitro: elevated ROS level, membrane damage, apoptosis in vivo: induced magnetic hyperthermia and antitumor | [ |
| MWCNTs | 10 ~ 20 | bare | neurovascular disorders | – | – | Wistar rats | intraperitoneal injection for 14 days | 2.5 | induction of autophagy LC3 ↑, Beclin 1 ↑, P62↓ | impaire the congnitive ability of rats | [ |
| Acid NPs | 102 ± 19 | PEG | Liver Cancer | HepG2 cells | 50 | C57BL/6 J mice (6 weeks old) | intravenous injection for 14 days | 10 | induction of autophagy LC3 ↑ | in vitro: apoptosis, autophagic cell death in vivo: tumor growth inhibition | [ |
| SeNPs | ~ 240 | curcumin | Ehrlich s ascites carcinoma | HCT116 cells | 1,2,5,10,20 | Female Swiss albino mice | decrease autophagy LC3 ↓, Beclin 1 ↓ | In vitro: ROS production, MMP reduction in vivo: inhibition of tumor growth | [ | ||
| Fe3O4NPs | 51.34 ± 14.71 | bare | Lung cancer | A549 cells | 100 | – | – | – | induction of autophagy LC3 ↑ | ROS, mitochondrial damage necrosis, autophagic cell death | [ |
| Fe3O4 NPs | 162.6 ± 15.6 | Chitosan | Stomach cancer | SGC7901, SGC7901/ADR cells | 10 | nude mice (5–6 weeks old) | intravenous injection for 28 days | 5 | induction of autophagy LC3 ↑ | in vitro: mitochondrial dysfunction, excessive ROS, DNA damage, cell death in vivo: tumor growth inhibition | [ |
| ZnO NPs | 50 | bare | oral cancer | CAL 27 cells | 25 | – | – | – | induction of autophagy LC3 ↑, Beclin 1 ↑, P62↓ | ROS, mitochondrial dysfunction, cell death | [ |
| Ag NPs | 26.5 ± 8.4 | bare | melanoma | HeLa cells | 2,5,10,15,20 | Male C57BL/ 6 mice (6–8 weeks old) | subcutaneous injection for 4 days | 1.5 | induction of autophagy autophagosome accumulation | in vitro: inhibition of apoptosis in vivo: promote tumor growth | [ |
| CuS NPs | – | bare | Prostate Cancer | RWPE-1 cells | 80,120,160 | nude male mice (4–8 weeks old) | intraperitoneal injection for 3 weeks | 120(μg/ml) | Autophagy blockage LC3 ↑ | In vitro: autophagosome accumulation In vivo: inhibit prostate tumor growth with NIR-light | [ |
| Lactoferrin nanostructures | 137.0 ± 33.65 | bare | AD | PC12 cells | 10uM | Wistar rats | intraperitoneal injection for 7 days | 5 | induction of autophagy Atgs ↑, LC3 ↑ | in vitro: apoptosis inhibition, neuroprotective effect in vivo: improved spatial memory and learning | [ |
| C60 fullerene | – | PEG | AD | Neuro-2A cells | 10uM | – | – | – | induction of autophagy LC3 ↑ | apoptosis inhibition, cell survival, neuroprotective effect | [ |
| CuS NPs | 11 ± 2.6 | bare | Atherosclerosis | VSMCs | 0.4 | male mice (6–8 weeks old) | intragastric administration for 12 weeks | 10 | induction of autophagy LC3 ↑ | in vitro: reduced VSMC foam cell formation, enhanced cholesterol efflux in vivo: inhibition of VSMC foam cell formation and attenuation of atherosclerotic lesion in mice | [ |
| Fum-PD NPs | 252 | bare | Arthritis | SEVC4 | 20 nM | male C57BL/6 mice (6–8 weeks old) | intravenous injection for 9 days | 0.3 | induction of autophagy LC3 ↑, LAMP-1 ↑, p62↓ | in vitro: enhanced NO production, inhibited inflammation in vivo: inflammatory response and inflammatory | [ |
Fig. 4Dual role of cancer cell-associated autophagy in cancer progression. This figure depicts recently described mechanisms supporting a tumor suppressor or tumor promoter role for autophagy. a Autophagy as tumor suppressor mechanism. (1) Functional autophagy acts as a quality control mechanism that, under stressed conditions, either restores homeostasis or induces senescence, thus preventing tumorigenesis. (2) Genomic instability, chronic inflammation, p62 accumulation, or increased inflammation associated with tumor initiation and progression under conditions of defective autophagy support a tumor suppressor role for autophagy in cancer progression. b Autophagy as tumor promoter mechanism. (1) ‘Autophagy addiction’, especially observed in hypoxic regions of solid tumors, and decreased anoikis help sustain cancer cell viability by promoting malignant growth and metastasis. (2) The increased cancer cell death, especially in hypoxic regions, and reduction of tumor growth and metastasis observed under conditions of autophagy defects indicate that autophagy is a tumor-promoting mechanism in solid tumors [206]. Copyright (2013), with permission from Elsevier
In vivo toxicological studies of NPs mediated autophagy
| NPs | Size (nm) | Coating | Animal model | Administration | Dose (mg/kg BW) | Exposure time | Organ toxicity | Autophagy alterations | References |
|---|---|---|---|---|---|---|---|---|---|
| TiO2 NPs | 19.3 ± 5.4 | bare | A/J Jms Slc mice (5 weeks old) | inhalation | 2.5,5.0,10.0 (mg/m3) | 6 h per day for 4 weeks | 1. hyperplasia and hemorrhage 2. inflammatory response in the lung | induction of autophagy LC3 ↑ Beclin 1 ↑ | [ |
| Cd-based QDs | 12 | bare | male Balb/c mice | tail vein | 0.1 ~ 0.3 nmol | 24 h | 1. increase of aspartate transaminase and glutamate pyruvate transaminase 2. haemocytes and necrosis in the live and kidney | stimulated autophagic flux LC3 ↑ P62 ↓ | [ |
| ZnO NPs | 47.8 | bare | Female Balb/c mice (8 weeks old) | Intraperitoneal or intravenous injection | 10 | once per week for 4 weeks | increase in serum creatinine and BUN in the kidney | autophagy induction autophagosome accumulation, LC3 ↑ | [ |
| 200–250 | bare | Balb/c mice (6–8 weeks old) | oral gavage | 200, 500 | 6 days | massive infiltration of inflammatory cells and DNA damage in the liver | autophagy induction autophagosome accumulation | [ | |
| UCNs | < 200 | bare | male C57BL/6 J mice (6–8 weeks old) | tail vein | 100 | 24 h | 1. inflammatory cell infiltrates 2. ALT levels increased in the liver | induction of autophagy autophagosomes accumulation LC3 ↑ LAMP ↑ | [ |
| PAMAM NPs | 5 ~ 6 | bare | female Balb/c mice (6–8 weeks old) | intraperitoneal injection | 100 | 10 days | 1. hepatocytic necrosis and vacuolization 2. weight decreased 3. ALT and AST increased in the liver | induction of autophagy accumulation of vacuolization LC3 ↑ | [ |
| Graphene nanoplatelets | 3 ~ 4 | bare | ICR mice 6 Weeks old) | intratracheal instillation | 2.5, 5 | 1, 7, 14, and 28 days | 1. hyperplasia and hemorrhage 2. inflammatory response in the lung | blockade of autophaic flux LC3 ↑ P62 ↑ | [ |
| PAMAM NPs | _ | bare | male Balb/c mice (6–10 weeks old) | intratracheal administration | 50 | 24 h | lung inflammation and changed the lung elastance | induction of autophagy LC3 ↑ | [ |
| SWCNTs | – | COOH-CNT PABS-CNT PEG-CNT | male Balb/c mice(6–8 weeks old) | intratracheal administration | 15 | 24 h | 1. Acute pulmonary inflammation 2. severe lung edema | induction of autophagy autophagosomes accumulation LC3↑ | [ |
| CdTe QDs | 4.08 | bare | male Balb/c mice (8–10 weeks old) | intravenous injection | 8 and 16 nmol/kg | 24 h | 1. increase in uric acid, creatinine and BUN 2. UPR and ER-phagy in the kidney and liver | induction of autophagy LC3↑ | [ |
| Fe3O4 NPs | 15 ~ 20 | PLGA | NIH mice | intraperitoneal injection | 10 | 2, 4, 8, 10 and 12 days | extensive accumulation of autophagosome in the kidney and spleen | induction of autophagy autophagosomes accumulation LC3 ↑ | [ |
| MWCNTs | 10 ~ 12 | bare | male Wistar rats (200–220 g) | intraperitoneal injection | 2.5 | once per day for 14 days | decrease in hippocampal synaptic plasticity and spatial cognition in the brain | induction of autophagy LC3 ↑ Becline ↑ | [ |
| CoCr NPs | 80 ± 14.6 | bare | C57BL/6 mice (12 weeks old) | intravenous injection | 0.12 mg per mouse | 9.5, 12.5 days of pregnancy | 1. increase in GFAP in hippocampus; 2. release IL-6 and DNA injury in the brain | blockade of autophaic flux LC3 ↑ P62 ↑ | [ |
| SiNPs | 62 | bare | Male and female ICR mice (8 weeks old) | intravenous injection | 29.5, 103.5 and 177.5 | 14 ays | 1.inhibitory effect on the expression of ICAM-1 and VCAM-1 2. impair angiogenesis | induction of autophagy LC3 ↑ | [ |